Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
08:30am, Tuesday, 31'st Mar 2026
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 20
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:31am, Thursday, 19'th Mar 2026
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. One analyst h
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application
08:30am, Tuesday, 17'th Mar 2026
FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations
PolyPid Announces Participation in Upcoming Investor Conferences
08:35am, Wednesday, 25'th Feb 2026
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcom
PolyPid Q4 Earnings Call Highlights
02:08am, Friday, 13'th Feb 2026
PolyPid (NASDAQ: PYPD) said 2025 marked a "pivotal year" as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
03:24pm, Wednesday, 11'th Feb 2026
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
07:30am, Wednesday, 11'th Feb 2026
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
08:00am, Wednesday, 28'th Jan 2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced th
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
08:30am, Tuesday, 16'th Dec 2025
Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Tran
PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
04:42pm, Wednesday, 10'th Dec 2025
PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
08:30am, Wednesday, 03'rd Dec 2025
PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
08:30am, Tuesday, 25'th Nov 2025
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀
PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript
12:51pm, Wednesday, 12'th Nov 2025
PolyPid Ltd. ( PYPD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Dikla Akselbrad - CEO & Director Ori Warshavsky - Chief Operating Officer - US Jonny Missulawin - Chief F
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
07:30am, Wednesday, 12'th Nov 2025
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
08:30am, Thursday, 06'th Nov 2025
PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced
